Benchmark Co. Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
A Quick Look at Today's Ratings for OmniAb(OABI.US), With a Forecast Between $8 to $11
OmniAb Analyst Ratings
OmniAb's Robust Pipeline and Strategic Positioning Drive Buy Rating Despite Macroeconomic Challenges
RBC Capital Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
OmniAb (OABI) Receives a Buy From RBC Capital
TD Cowen Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating
Craig-Hallum Sticks to Its Buy Rating for OmniAb (OABI)
RBC Capital Maintains OmniAb(OABI.US) With Buy Rating, Raises Target Price to $8
Benchmark Co. Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and OmniAb (OABI)
OmniAb Analyst Ratings
RBC Capital Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $7
Analysts Offer Insights on Healthcare Companies: OmniAb (OABI), Avadel Pharmaceuticals (AVDL) and Regulus (RGLS)
OmniAb Analyst Ratings
HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
RBC Capital Keeps Their Buy Rating on OmniAb (OABI)
Buy Rating Affirmed for OmniAb Amid Solid Financials and Promising Growth Prospects